25 completed, 6 terminated, 3 active not recruiting, 1 withdrawn. 17 Phase 2, 15 Phase 1, 2 Phase 3, 1 Not applicable.
Follow Endocyte: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer 225^Ac-PSMA-617, 68^Ga-PSMA-11 - Prostatic Neoplasms, Castration-Resistant | Phase 1 | Active not recruiting | Endocyte | 101 | 2021-04-01 | 2026-04-30 |
| Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer Lu-PSMA, Enzalutamide - Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Active not recruiting | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 162 | 2020-08-17 | 2026-06-22 |
| Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy 177Lu-PSMA-617 - Prostatic Neoplasms | Phase 1 / Phase 2 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 20 | 2020-08-06 | 2024-11-08 |
| Imaging Activated Macrophages in the Lungs Ga-EC2115 - COPD | Phase 1 | Terminated | Vanderbilt University Medical Center | 13 | 2018-11-29 | 2021-08-11 |
| Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer 177Lu-PSMA-617, Best supportive/best standard of care - Prostate Cancer | Phase 3 | Completed | Endocyte | 861 | 2018-05-29 | 2025-01-13 |
| A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer 177Lu-PSMA617, Cabazitaxel - Cancer of the Prostate, Metastatic Cancer | Phase 2 | Completed | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 201 | 2018-01-29 | 2022-06-13 |
| Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy 177Lu-PSMA-617 - Metastatic Castration Resistant Prostate Cancer | Phase 2 | Terminated | Endocyte | 71 | 2017-07-12 | 2021-03-24 |
| An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery EC1456, 99mTc-Etarfolatide - Ovary Cancer | Phase 1 | Completed | Endocyte | 3 | 2017-01-24 | 2019-02-07 |
| Phase 1 of EC1169 In Patients With Recurrent MCRPC EC1169, EC0652 - Prostate Cancer | Phase 1 | Completed | Endocyte | 40 | 2014-05-01 | 2019-02-07 |
| Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004) Vintafolide 2.5 mg, Paclitaxel 80 mg/m^2, Etarfolatide - Breast Neoplasms | Phase 2 | Withdrawn | Endocyte | 2014-04-01 | 2014-12-19 | |
| A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011) Vintafolide - Solid Tumor | Phase 1 | Terminated | Endocyte | 3 | 2014-02-01 | 2015-02-10 |
| Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors EC1456 and EC20 - Solid Tumors, Non Small Cell Lung Carcinoma | Phase 1 | Completed | Endocyte | 93 | 2013-10-01 | 2019-02-07 |
| Evaluation of the Biodistribution and Safety of 99mTC-Etarfolatide (EC20) in Normal Volunteers Etarfolatide (EC20) - Healthy | Phase 1 | Completed | Endocyte | 23 | 2013-04-01 | 2014-07-29 |
| A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001) Vintafolide, Carboplatin, Paclitaxel - Advanced Cancer | Phase 1 | Terminated | Endocyte | 37 | 2012-12-01 | 2015-02-10 |
| Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) EC145, Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®), placebo - Ovarian Cancer | Phase 3 | Terminated | Endocyte | 441 | 2011-04-22 | 2021-09-30 |
| Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer EC145, EC145 + Docetaxel, Docetaxel - Non Small Cell Lung Cancer | Phase 2 | Completed | Endocyte | 203 | 2011-03-01 | 2021-04-01 |
| A Study of FolateScan in Patients With Knee Osteoarthritis 99mTc-EC20 - Knee Osteoarthritis | Completed | Virginia Kraus | 25 | 2010-10-01 | 2012-11-27 | |
| Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010) EC145 - Solid Tumors | Phase 2 | Completed | Endocyte | 1 | 2009-12-31 | 2021-04-08 |
| Study of EC0489 for the Treatment of Refractory or Metastatic Tumors EC0489, Injection, EC20 - Cancer | Phase 1 | Completed | Endocyte | 65 | 2009-04-01 | 2012-08-08 |
| Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) Vintafolide, pegylated liposomal doxorubicin (PLD), EC20 - Ovarian Cancer | Phase 2 | Completed | Endocyte | 162 | 2008-09-01 | 2015-01-07 |
Showing 20 of 35. Sign in to see all of them.
Neoplasms (11) · Ovarian Neoplasms (8) · Neoplasm Metastasis (5) · Prostatic Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Adenocarcinoma (3) · Carcinoma, Renal Cell (3) · Endometrial Neoplasms (3) · Recurrence (3) · Osteoarthritis (2) · Adenocarcinoma of Lung (1) · Arthritis, Rheumatoid (1) · Breast Neoplasms (1) · Carcinoma, Ovarian Epithelial (1) · Crohn Disease (1)
EC145 (9) · Pluvicto (4) · technetium 99m etarfolatide (4) · Folic Acid (3) · GPI0100 (2) · Interferon-alpha (2) · Interleukin-2 (2) · Introns (2) · Paclitaxel (2) · aldesleukin (2) · fluorescein isothiocyanate-keyhole limpet hemocyanin (2) · liposomal doxorubicin (2) · (225)Ac-PSMA-617 (1) · Carboplatin (1) · Docetaxel (1)
United States (21) · Australia (4) · Canada (2) · Belgium (1) · Denmark (1) · France (1) · Germany (1) · Netherlands (1) · Puerto Rico (1) · South Africa (1) · Sweden (1) · United Kingdom (1)
Alison Armour, MD (2) · Binh Nguyen, MD, PhD (2) · Richard A Messmann, MD, MHS, BSc (2) · Alison Armour, MB ChB, BSc, MSc, MD, MRCP (1) · Beth Safirstein, MD (1) · Binh Nguyen, MD (1) · David M. Gershenson, MD (1) · Declan Murphy (1) · Eric L Matteson, M.D., M.P.H. (1) · James W. Fletcher, MD (1) · John Violet (1) · Louise Emmett, MBBS, FRACP (1) · Michael Hofman, A/Prof (1)
PMID 31595044, PMID 18952896, PMID 19473565, PMID 19837906, PMID 23032618, PMID 24127448, PMID 24667717, PMID 27084348, PMID 31196179, PMID 33189510, PMID 33581798, PMID 34161051, PMID 34246328, PMID 34373282, PMID 36261050, PMID 36350899, PMID 37230533, PMID 37269841, PMID 37407274, PMID 37891072, PMID 38043558, PMID 38050121, PMID 38185538, PMID 38534939, PMID 38621400, PMID 39031642, PMID 39162634, PMID 39242323, PMID 39430616, PMID 39956124, PMID 40425844, PMID 40752515, PMID 41956861, PMID 41979224, PMID 41986500, PMID 42048586
2018 (1)